霉酚酸酯在肾移植术后的临床应用  

Clinical use of mycophenolate mofetil in renal taransplation

作　　者：董亚琳[1] 王茂义[1] 黄猛 田普训[2] 庞胜强 

机构地区：[1]西安医科大学第一附属医院药剂科,西安710061 [2]西安医科大学第一附属医院肾移植科,西安710061

出　　处：《中国临床药理学与治疗学》1999年第4期313-315,共3页Chinese Journal of Clinical Pharmacology and Therapeutics

摘　　要：目的 通过监测肾移植术后患者环孢霉素A(CsA)的全血浓度,探讨CsA在霉酚酸酯(MMF)参与的三联免疫抑制用药方案中的理想治疗窗.方法 用特异性荧光偏振免疫法测定CsA全血浓度.依术后时间及三联免疫抑制方案的不同分组,并对CsA治疗窗进行比较.结果 MMF方案中CsA在肾移植术后＜1mon、1~3mon、3~6mon的理想治疗窗分别为150~300μg·L^(-1)120~260μg·L^(-1)和100~225μg·L(-1).结论 MMF方案优于经典方案,可安全、有效预防移植术后的排异和毒性反应.Aim To monitor the whole blood trough concentration of cyclosporine A (CsA) in renaltransplant recipients reciving triple therapy with mycophenolate mofetil, cyclosporine andprednisone and to establish an optimal therapeutic window of CsA. Methods Sampleswere measured by specific fluorescence polarization immunoassay. According to the timeafter operation and different therapy plan, the whole blood trough concentration of CsA ineach group was compared with that in control group.Results The optimal therapeuticwindow of CsA with MMF plan was 150~300 μg· L-1 (less than one month after op-eration), 120~260μg·L-1 (1~ < 3 mon) and 100~225 μg· L-1 (3~ < 6 mon). Con-clusions The optimal therapeutic window of CsA with MMF plan are lower than controlgroups in the incidence of toxic effects and the rejection reaction is diminished obviously.

关 键 词：霉酚酸酯 环孢霉素 肾移植 临床应用 

分 类 号：R976[医药卫生—药品] R699.2[医药卫生—药学]